3,4-dihydro-(1H)-quinoline-2-thione | 41493-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3,4-dihydro-(1H)-quinoline-2-thione
• 英文别名: 3,4-dihydro-1H-quinoline-2-thione；3,4-dihydroquinoline-2(1H)-thione；3,4-dihydro-1H-quinoline-2-thione；3,4-Dihydro-1H-chinolin-2-thion；3,4-Dihydrothiocarbostyril；2(1H)-Quinolinethione, 3,4-dihydro-
• CAS: 41493-89-4
• 化学式: C₉H₉NS
• 分子量: 163.243
• InChiKey: UMHLZGJTGWFCGD-UHFFFAOYSA-N

物化性质

• 熔点：
  105 °C
• 沸点：
  266.5±43.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  44.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-(1H)-quinoline-2-thione 在 4-dimethylaminopyridine borane 、 di-tert-butoxydiazene 、 苯硫酚 作用下， 以 甲苯 为溶剂， 以82%的产率得到1,2,3,4-四氢喹啉
  参考文献：
  名称：

  Lewis Base–Boryl Radicals Enabled the Desulfurizative Reduction and Annulation of Thioamides

  摘要：

  A new protocol for radical transformations of thioamides promoted by Lewis base-boryl radicals is reported. The desulfurizative reduction to access organic amines was enabled utilizing 4-dimethylaminopyridine-BH3 as the boryl radical precursor and PhSH as the polarity reversal catalyst. Alternatively, the chain process for unsaturated thioamides was switched to an annulation reaction using N-heterocyclic carbene BH3 as the boryl radical precursor and sterically bulky Ph3CSH as the catalyst, allowing for the construction of N-heterocyclic and carbocyclic skeletons.

  DOI：

  10.1021/acs.orglett.7b03201
• 作为产物：
  描述：

  o-aminophenylethyl bromide 在 劳森试剂 、 palladium diacetate 、 sodium carbonate 、 二乙胺 作用下， 以 丙酮 、 甲苯 为溶剂， 50.0 ℃ 、200.0 kPa 条件下， 反应 14.0h， 生成 3,4-dihydro-(1H)-quinoline-2-thione
  参考文献：
  名称：

  具有药物活性的苯并噁嗪并吡唑-钙配合物的制备方法

  摘要：

  本发明公开了一种具有药物活性的苯并噁嗪并吡唑‑钙配合物的制备方法，属于药物合成技术领域。本发明的技术方案要点为：本发明与现有技术相比具有以下有益效果：本发明合成方法简单、分子结构新颖且所得到化合物抗血小板聚集效果与噻氯匹定相当。

  公开号：

  CN107325098A
• 作为试剂：
  描述：

  2-氯苯基环氧乙烷 在 (11bS)-4-羟基-2,6-二[2,4,6-三(异丙基)苯基]-二萘并[2,1-d:1',2'-f][1,3,2]二氧杂磷杂卓4-氧化物 、 3,4-dihydro-(1H)-quinoline-2-thione 作用下， 以 氯仿 为溶剂， 反应 101.0h， 以84%的产率得到
  参考文献：
  名称：

  环氧化物催化对映选择性转化为硫杂丙烷

  摘要：

  已开发出一种高效且对映选择性的布朗斯台德酸催化环氧化物向硫杂丙烷的转化。该反应以动力学拆分进行，以高产率和对映体纯度提供环氧化物和硫杂丙环。催化剂和硫供体之间的异二聚体形成提供了一种防止催化剂分解的有效方法，并使催化剂负载量低至 0.01 mol%。

  DOI：

  10.1021/jacs.6b01960

文献信息

• ORGANIC COMPOUNDS
  申请人：Breitenstein Werner

  公开号：US20090233920A1

  公开（公告）日：2009-09-17

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.

  该发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=紊乱）；该类化合物用于制备用于治疗依赖肾素活性疾病的药物配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的药物配方，和/或包括给予3,5-取代哌啶化合物的治疗方法，一种用于制造3,5-取代哌啶化合物的方法，以及其合成的新中间体和部分步骤。优选的化合物（也可以存在为盐）具有式I的结构，其中R1、R2、T、R3和R4如规范中定义。
• HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20170158680A1

  公开（公告）日：2017-06-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由公式（I）表示的杂环化合物，其立体异构体，或其药用可接受的盐，其药物组合物，以及它们用于制备预防或治疗中枢神经系统疾病的药物。
• 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE
  申请人：Horiuchi Yoshihiro

  公开号：US20120225876A1

  公开（公告）日：2012-09-06

  Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R 1a and R 1b may be the same or different and each independently represents a C 1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X 1 represents a hydroxyl group or an aminocarbonyl group; Z 1 represents a single bond or the like; and R 2 represents an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group or the like.)

  公开了一种由公式(1)表示的化合物或其药理可接受的盐(在公式中，A代表由公式(A-1)表示的基团；R1a和R1b可以相同或不同，每个独立地表示一个可以由一个到三个卤素原子取代的C1-6烷基；m和n各自独立地表示0-5之间的整数；X1代表羟基或氨基甲酰基；Z1代表单键等；R2代表一个可选地取代的C1-6烷基，一个可选地取代的C6-10芳基等)。
• Substituted Piperdines as Renin Inhibitors
  申请人：Ehara Takeru

  公开号：US20090137566A1

  公开（公告）日：2009-05-28

  The invention relates to substituted 3,4- or higher substituted piperididine compounds, the use thereof for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; pharmaceutical formulations or products comprising said compounds, and/or a method of treatment comprising administering said compounds, a method for the manufacture of said compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis. The compounds preferably have the formula I, wherein the moieties R1, R2, R11 and W are as defined in the specification.

  该发明涉及替代的3,4-或更高替代的哌啶基化合物，其用于制备用于治疗依赖肾素活性的疾病的药物配方；该类化合物在治疗依赖肾素活性的疾病中的应用；这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病的治疗；包括上述化合物的药物配方或产品，以及/或包括上述化合物的给药方法，制备上述化合物的方法，以及用于其合成的新中间体、起始材料和/或部分步骤。这些化合物优选具有公式 I，其中基团 R1、R2、R11 和 W 如规范中所定义。
• [EN] N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'AMINE N-ACYLE CYCLIQUE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2011111875A1

  公开（公告）日：2011-09-15

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, -C(O)-, etc.; W2 is C1- alkylene; W3 is a single bond, methylene, -NH-, -CR4=CR5-, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了一种化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，同时减少了传统的副作用风险，并对与精神分裂症以外的认知功能障碍相关的中枢神经系统疾病具有显著效果。提供了式（1）的N-酰基环胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4=CR5-等；环Q是式（a）的一组，其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a、R1b和R1c分别是相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药用可接受盐。